ArticlePloS one2018
Natural biocide cocktails: Combinatorial antibiotic effects of prodigiosin and biosurfactants.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Acoustic virtual walls enable open, scalable, and programmable microfluidics.Science advances · 2026Article
- Metabolite diversification via halogen salts enhances biocontrol potential of marine-derived Trichoderma virens B211.Natural products and bioprospecting · 2026Article
- Synthesis of Lipopeptides Using Vegetable Oils by Newly Isolated Strain ofInternational journal of molecular sciences · 2025Article
- Application of microbial pigments in the pharmaceutical industry: current status and opportunities.Archives of microbiology · 2025Review
- Transcriptomic analysis of cell envelope inhibition by prodigiosin in methicillin-resistantFrontiers in microbiology · 2024Article
- Isolation, Identification, and Antibacterial Properties of Prodigiosin, a Bioactive Product Produced by a NewAntibiotics (Basel, Switzerland) · 2023Article
- Biotechnological potential of microbial bio-surfactants, their significance, and diverse applications.FEMS microbes · 2023Review
- Production of tailored hydroxylated prodiginine showing combinatorial activity with rhamnolipids against plant-parasitic nematodes.Frontiers in microbiology · 2023Article
- Recent Advances in Prodigiosin as a Bioactive Compound in Nanocomposite Applications.Molecules (Basel, Switzerland) · 2022Review
- Microfluidics in Biotechnology: Overview and Status Quo.Advances in biochemical engineering/biotechnology · 2022Review
- Natural Pigments of Bacterial Origin and Their Possible Biomedical Applications.Microorganisms · 2021Review
- Seed treatment with prodigiosin controls damping-off of cucumber caused by Pythium ultimum.AMB Express · 2021Article
- A Metabolomics and Molecular Networking Approach to Elucidate the Structures of Secondary Metabolites Produced byFrontiers in chemistry · 2021Article
- Article
- Antifungal Activity of Polyoxometalate-Ionic Liquids on Historical Brick.Molecules (Basel, Switzerland) · 2020Article
- Synergistic bactericidal profiling of prodigiosin extracted from Serratia marcescens in combination with antibiotics against pathogenic bacteria.Microbial pathogenesis · 2020Article
- Tetracycline Water Soluble Formulations with Enhanced Antimicrobial Activity.Antibiotics (Basel, Switzerland) · 2020Article
- Screening an Established Natural Product Library Identifies Secondary Metabolites That Potentiate Conventional Antibiotics.ACS infectious diseases · 2020Article
- Microfluidic systems for rapid antibiotic susceptibility tests (ASTs) at the single-cell level.Chemical science · 2020Review
- Biologically active pigment and ShlA cytolysin of Serratia marcescens induce autophagy in a human ocular surface cell line.BMC ophthalmology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial secondary metabolites are naturally produced to prevail amongst competitors in a shared habitat and thus represent a valuable source for antibiotic discovery. The transformation of newly discovered antibiotic compounds into effective drugs often requires additional surfactant components for drug formulation. Nature may also provide blueprints in this respect: A cocktail of two compounds consisting of the antibacterial red pigment prodigiosin and the biosurfactant serrawettin W1 is naturally produced by the bacterium Serratia marcescens, which occurs in highly competitive habitats including soil. We show here a combinatorial antibacterial effect of these compounds, but also of prodigiosin mixed with other (bio)surfactants, against the soil-dwelling bacterium Corynebacterium glutamicum taken as a model target bacterium. Prodigiosin exerted a combinatorial inhibitory effect with all tested surfactants in a disk diffusion assay which was especially pronounced in combination with N-myristoyltyrosine. Minimal inhibitory and bactericidal concentrations (MIC and MBC) of the individual compounds were 2.56 μg/mL prodigiosin and 32 μg/mL N-myristoyltyrosine, and the MIC of prodigiosin was decreased by 3 orders of magnitude to 0.005 μg/mL in the presence of 16 μg/mL N-myristoyltyrosine, indicative of synergistic interaction. Investigation of bacterial survival revealed similar combinatorial effects; moreover, antagonistic effects were observed at higher compound concentrations. Finally, the investigation of microcolony formation under combined application of concentrations just below the MBC revealed heterogeneity of responses with cell death or delayed growth. In summary, this study describes the combinatorial antibacterial effects of microbial biomolecules, which may have ecological relevance by inhibiting cohabiting species, but shall furthermore inspire drug development in the combat of infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.